AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ADC Therapeutics Reports 89.8% ORR, 77.6% CR for ZYNLONTA Combo.
ByAinvest
Wednesday, Dec 3, 2025 7:33 am ET1min read
ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab for relapsed or refractory DLBCL. The combination demonstrated an 89.8% overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with at least 6 months of follow-up. The safety profile was manageable, and the trial is on track to complete enrollment in 1H 2026. Data will be shared at a medical meeting and submitted for publication by end of 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet